自拟痛风汤剂治疗浊瘀痹结型痛风性关节炎临床疗效和安全性分析

An analysis of safety and clinical efficacy of the Tongfeng decoction on urarthritis of the Zhuoyu Bijie type

目的:评价自拟痛风汤剂治疗浊瘀痹结型痛风性关节炎临床疗效和安全性。方法:选择2017年11月-2018年11月来我院进行治疗的浊瘀痹结型痛风性关节炎患者78例,按照抽签法的要求对其分组,平均分成实验组(39例:自拟痛风汤剂)与对照组(39例:秋水仙碱),分析血尿酸以及血沉数据、半年之后的治疗效果与复发率。结果:实验组血尿酸(311.2±10.1)μmol/L,血沉(16.3±1.1)mm/h;对照组血尿酸(566.2±11.3)μmol/L,血沉(24.5±2.2)mm/h;实验组治疗效果为97.4%,对照组为76.9%,实验组的血尿酸以及血沉数据、半年之后的治疗效果与复发率优于对照组,数据之间的比较呈现出明显的差异性,P <0.05。结论:在浊瘀痹结型痛风性关节炎实际治疗的过程中,采用自拟痛风汤剂,有助于促使血尿酸数值的改善,有着很好的推广优势。

Objective: To explore the safety and clinical efficacy of the Tongfeng decoction(痛风汤剂) on urarthritis of Zhuoyu Bijie type(浊瘀痹结型). Methods: 78 patients with urarthritis of Zhuoyu Bijie type who came to our hospital from November 2017 to November 2018 were divided into experiment groups(39 cases: Tongfeng decoction) and the control group(39 cases: colchicine) according to the requirements of the lottery method. Analysis of blood uric acid and erythrocyte sedimentation rate, treatment efficacy and recurrence rate after half a year. Results: The experiment group blood uric acid(311.2±10.1) μmol/L, erythrocyte sedimentation rate(16.3±1.1) mm/h, the control group blood uric acid(566.2±11.3) μmol/L, erythrocyte sedimentation rate(24.5±2.2) mm/h. The experiment group therapeutic efficacy was 97.4%. The control group was 76.9%. The blood uric acid and erythrocyte sedimentation rate of the experimental group and the treatment efficacy and recurrence rate after half a year were better than the control group. The comparison between the data showed obvious difference,P<0.05. Conclusion: In the actual treatment of urarthritis of the Zhuoyu Bijie type, the use of the Tongfeng decoction can help to improve the value of blood uric acid, and has a good promotion advantage.